LPS converts Gr-1+CD115+ myeloid-derived suppressor cells from M2 to M1 via P38 MAPK

Experimental Cell Research

Volumn 319, Issue 12, 2013, Pages 1774-1783

  Yang, Yi ^a   Zhang, Ruihua ^a   Xia, Fei ^a   Zou, Ting ^a   Huang, Anfei ^a   Xiong, Sidong ^a   Zhang, Jinping ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Lewis lung carcinoma; Lipopolysaccharide; Tumor associated macrophage

Indexed keywords

ARGINASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; GR 1+ CD115 MONOCYTE; IMMUNOFLUORESCENCE; IN VITRO STUDY; LEWIS CARCINOMA; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

BACTERIA (MICROORGANISMS); MUS;

EID: 84879602153     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.05.007     Document Type: Article

References (41)

1. Gabrilovich D.I., Bronte V., Chen S.H., Colombo M.P., Ochoa A., Ostrand-Rosenberg S., Schreiber H. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 2007, 67:425.
2. Youn J.I., Nagaraj S., Collazo M., Dmitry I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 2008, 181:5791-5802.
3. Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 2007, 117:1155-1166.
4. Kusmartsev S., Gabrilovich D.I. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol. Immunother. 2006, 55:237-245.
5. Rabinovich G.A., Gabrilovich D.I., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 2007, 25:267-296.
6. Talmadge J.E. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin. Cancer Res. 2007, 13:5243-5248.
7. + population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 2007, 204:1463-1474.
8. Gomez-Garcia L., Lopez-Marin L.M., Saavedra R., Reyes J.L., Rodriguez-Sosa M., Terrazas L.I. Intact glycans from cestode antigens are involved in innate activation of myeloid suppressor cells. Parasite Immunol. 2005, 27:395-405.
9. Ezernitchi A.V., Vaknin I., Cohen-Daniel L., Levy O., Manaster E., Halabi A., Pikarsky E., Shapira L., Baniyash M. TCR downregulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J. Immunol. 2006, 177:4763-4772.
10. MacDonald K.P., Rowe V., Clouston A.D., Welply J.K., Kuns R.D., Ferrara J.L., Thomas R., Hill G.R. Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J. Immunol. 2005, 174:1841-1850.
11. Paraiso K.H., Ghansah T., Costello A., Engelman R.W., Kerr W.G. Induced SHIP deficiency expands myeloid regulatory cells and abrogates graft-versus-host disease. J. Immunol. 2007, 178:2893-2900.
12. Sawanobori Y., Ueha S., Kurachi M., Shimaoka T., Talmadge J.E., Abe J., Shono Y., Kitabatake M., Kakimi K., Mukaida N., Matsushima K. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008, 111:5457-5466.
13. Ochoa A.C., Zea A.H., Hernandez C., Rodriguez P.C. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 2007, 13:721s-726s.
14. Almand B., Clark J.I., Nikitina E., van Beynen J., English N.R., Knight S.C., Carbone D.P., Gabrilovich D.I. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 2001, 166:678-689.
15. Mirza N., Fishman M., Fricke I., Dunn M., Neuger A.M., Frost T.J., Lush R.M., Antonia S., Gabrilovich D.I. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006, 66:9299-9307.
16. Fricke I., Mirza N., Dupont J., Lockhart C., Jackson A., Lee J.H., Sosman J.A., Gabrilovich D.I. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 2007, 13:4840-4848.
17. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., McDermott D., Quiceno D., Youmans A., O'Neill A., Mier J., Ochoa A.C. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005, 65:3044-3048.
18. Hoechst B., Voigtlaender T., Ormandy L., Gamrekelashvili J., Zhao F., Wedemeyer H., Lehner F., Manns M.P., Greten T.F., Korangy F. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 2009, 50:799-807.
19. Solito S., Bronte V., Mandruzzato S. Antigen specificity of immune suppression by myeloid-derived suppressor cells. J. Leukoc. Biol. 2011, 90:31-36.
20. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumorbearing host. Cancer Res. 2006, 66:1123-1131.
21. + T cells. J. Clin. Invest. 2006, 116:2777-2790.
22. + T cell proliferation via an IFN-gamma and nitric oxide-dependent mechanism. J. Immunol. 2001, 167:4293-4302.
23. Kryczek I., Zou L., Rodriguez P., Zhu G., Wei S., Mottram P., Brumlik M., Cheng P., Curiel T., Myers L., Lackner A., Alvarez X., Ochoa A., Chen L., Zou W. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 2006, 203:871-881.
24. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Annu. Rev. Immunol. 2005, 23:515-548.
25. Flies D.B., Chen L. The new B7s: playing a pivotal role in tumor immunity. J. Immunother. 2007, 30:251-260.
26. Garcia M.R., Ledgerwood L., Yang Y., Xu J., Lal G., Burrell B., Ma G., Hashimoto D., Li Y., Boros P., Grisotto M., van Rooijen N., Matesanz R., Tacke F., Ginhoux F., Ding Y., Chen S.H., Randolph G., Merad M., Bromberg J.S., Ochando J.C. Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. J. Clin. Invest. 2010, 120:2486-2496.
27. Umemura N., Saio M., Suwa T., Kitoh Y., Bai J., Nonaka K., Ouyang G.F., Okada M., Balazs M., Adany R., Shibata T., Takami T. Tumor-infiltrating myeloid derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J. Leukoc. Biol. 2008, 83:1136-1144.
28. Guruvayoorappan C. Tumor versus tumor-associated macrophages: How hot is the link?. Integr. Cancer Ther. 2008, 7:90-95.
29. Mantovani A., Sica A., Allavena P., Garlanda C., Locati M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum. Immunol. 2009, 70:325-330.
30. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
31. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M.G., Rimoldi M., Biswas S.K., Allavena P., Mantovani A. Macrophage polarization in tumour progression. Semin. Cancer Biol. 2008, 18:349-355.
32. Sinha P., Clements V.K., Miller S., Ostrand-Rosenberg S. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol. Immunother. 2005, 54:1137-1142.
33. Sinha P., Clements V.K., Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 2005, 65:11743-11751.
34. Ma G., Pan P.Y., Eisenstein S., Divino C.M., Lowell C.A., Takai T., Chen S.H., Receptor-B Paired Immunoglobin-like Regulates the suppressive function and fate of myeloid-derived suppressor cells. Immunity 2011, 34:385-395.
35. Nyirenda M.H., O'Brien K., Sanvito L., Constantinescu C.S., Gran B. Modulation of regulatory T cells in health and disease: role of toll-like receptors. Inflamm. Allergy Drug Targets 2009, 8:124-129.
36. Bromberg J. Stat proteins and oncogenesis. J. Clin. Invest. 2002, 109:1139-1142.
37. Gabrilovich D.I., Nagaraj S. Myeloid-derived-suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
38. + myeloid cells. Cancer Res. 2006, 66:6807-6815.
39. Andreakos E., Sacre S.M., Smith C., Lundberg A., Kiriakidis S., Stonehouse T., Monaco C., Feldmann M., Foxwell B.M. Distinct pathways of LPS-induced NF-kb activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP. Blood 2004, 103:2229-2237.
40. Oikonomopoulou K., Brinc D., Kyriacou K., Diamandis E.P. Infection and cancer: revaluation of the hygiene hypothesis. Clin. Cancer Res. 2013, (Epub ahead of print) PubMed PMID: 23536438.
41. Saban M.R., O'Donnell M.A., Hurst R.E., Wu X.R., Simpson C., Dozmorov I., Davis C., Saban R. Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-alpha. BMC Immunol. 2008, 9:4.